Leptospirosis - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026 - 2031)

According to Mordor Intelligence, the leptospirosis market size is expected to grow from USD 617.61 million in 2025 to USD 654.05 million in 2026 and is forecast to reach USD 871.14 million by 2031 at 5.90% CAGR over 2026-2031.

This report is Segmented by Product Type (Diagnostics, Therapeutics), End User (Hospitals & Specialty Clinics, Diagnostic Reference Laboratories, and More), Distribution Channel (Hospital Pharmacies, Retail & Online Pharmacies, and More), and Geography (North America, Europe, Asia-Pacific, Middle East & Africa, South America). The Market Forecasts are Provided in Terms of Value (USD).

Global Leptospirosis Market Trends and Insights

Flooding And Extreme Rainfall Driven By Climate Change

In May 2024, flooding in Brazil's Rio Grande do Sul resulted in 1,314 reported cases and 55 fatalities, increasing the incidence rate to 12.1 per 100,000, significantly higher than the national average of 1.9 per 100,000. Concurrently, surveillance efforts identified 958 lab-confirmed infections, marking a 10.3-fold increase and prompting swift actions for procuring rapid tests and preventive antibiotics. In the Philippines, the first seven months of 2025 recorded 3,037 cases, reflecting a 121% increase from the previous year, attributed to Typhoon Hagupit. This surge led to the transition of LAMP testing to community clinics. New Zealand experienced its highest case load in 20 years following Cyclone Gabrielle, while the Netherlands saw a 4.1-fold rise in local infections in 2024, coinciding with intensified precipitation extremes. Such climatic events are transforming leptospirosis from a seasonal ailment, primarily affecting farm workers, to a pressing year-round public health concern, driving increased investments in diagnostics and treatments within the leptospirosis market.

Reinstating Leptospirosis As A Notifiable Disease

In August 2023, France reinstated mandatory reporting for leptospirosis. By 2024, 886 cases were recorded, with a notable 74% hospitalization rate. This data highlights the disease's burden and aids in setting procurement budget baselines. Following a 2023 decree in Argentina, confirmed cases increased 3.8-fold by epidemiological week 34 of 2025, emphasizing the need for rapid molecular assays. In January 2026, Australia expanded its national case definition to include PCR-positive results, broadening the range of reimbursable tests and boosting diagnostic demand. In the United States, weekly publications under the National Notifiable Diseases Surveillance System ensure hospitals remain vigilant, stabilizing order volumes for multiplex panels. Such regulatory measures are transforming previously latent testing demands into quantifiable, budgeted needs, thereby expanding the leptospirosis market.

Fragmented Reimbursement Pathways Hinder Progress on Neglected Tropical Diseases

Between 2018 and 2023, the World Health Organization reported a 41% decline in official development assistance for neglected tropical diseases, significantly reducing financial resources for new diagnostic developments. In India, Indonesia, and the Philippines, health insurance plans exclude coverage for leptospirosis tests, requiring patients to pay out of pocket amounts ranging from USD 15 to 40, which can represent up to a week's wages in rural areas. In Brazil, reimbursement is provided for outdated microscopic agglutination tests but not for advanced PCR tests. This policy directs laboratories toward slower, traditional technologies, even as the market shifts toward rapid molecular platforms for leptospirosis. These inconsistencies limit economies of scale for advanced assays, delaying price reductions and restraining the growth of the leptospirosis market.

Other drivers and restraints analyzed in the detailed report include:

1. Public-Sector Stockpiling Of Doxycycline And Ceftriaxone For Disaster Response
2. Tertiary Hospitals Adopting Multiplex Febrile-Illness PCR Panels
3. Reliance on Low-Margin Generic Antibiotics Stifles Private R&D Investment

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Diagnostics, contributing 55% of 2025 revenue, emphasize the transition of laboratory confirmation from an optional service to a clinical requirement. While serological ELISA and MAT kits remain dominant in reference labs, molecular assays now account for nearly one-third of diagnostic sales due to reagent prices dropping below USD 5 per run. The multiplex category is experiencing the fastest growth, with products like bioMerieux's BioFire Global Fever Panel and HiMedia's Acute Fever Panel delivering results in under an hour, enabling physicians to reduce broad-spectrum antibiotic therapy. Although smaller in size, therapeutics are projected to surpass diagnostics with a 6.35% CAGR through 2031. This growth is driven by the expansion of disaster-response stockpiles in Asia-Pacific and South America, ensuring consistent orders for generic manufacturers and strengthening the overall resilience of the leptospirosis market.

Geography Analysis

In 2025, North America accounted for 40.40% of global revenue, supported by mandatory weekly reporting by health authorities and government stockpiles, which established a consistent baseline for test and drug consumption in the regional leptospirosis market. Hospital formularies now predominantly feature multiplex panels, and reimbursement policies have evolved to tie payouts to documented etiology, steering practitioners away from broad-spectrum regimens. The United States operates over 50 state public-health laboratories equipped for same-day Leptospira PCR testing, ensuring sustained demand even in non-flood seasons.

Asia-Pacific is projected to grow at a compound annual growth rate (CAGR) of 6.95% through 2031, driven by the Philippines reporting significant case numbers in the first half of 2025 and India's substantial annual infections, many of which remain undiagnosed. Affordable LAMP tests, priced at approximately USD 3.50, are enabling mass screenings in community clinics, broadening the leptospirosis market's reach beyond urban tertiary centers. Australia's decision in early 2026 to include PCR in its case definition provides a boost from high-income regions, while Indonesia and Malaysia are expected to implement similar policy changes within the next two years.

In South America, demand is episodic, often spiking in response to floods. For example, Brazil's severe flooding in May 2024 led to a significant surge in confirmed cases within two months, prompting emergency purchases of rapid tests and large quantities of doxycycline. Meanwhile, Argentina's notification law highlighted diagnostic gaps, with the majority of 2025 cases concentrated in three provinces, a void that suppliers are now working to address. Europe experiences steadier growth but faces challenges due to varied reimbursement policies across its member nations. In Africa, while the burden of the disease remains largely uncharted, there is potential for significant growth once financial support improves.

1. Abbott Laboratories
2. Bayer
3. BioMerieux Inc.
4. Chembio Diagnostics
5. Dr. Reddy's Laboratories Inc.
6. Genomtec
7. GlaxoSmithKline
8. Johnson & Johnson
9. Lupin
10. Meridian Bioscience
11. Molbio Diagnostics Ltd.
12. Pfizer
13. QIAGEN
14. Roche
15. Novartis
16. Sanofi
17. Seegene
18. Sun Pharmaceuticals Industries
19. Thermo Fisher Scientific
20. Viatris (Mylan)

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support